Benzodiazepines in Hospice and Palliative Care: The Double-Edged Sword of Comfort, Cognition, and Clinical Judgment
Introduction: A Familiar Medication, An Uncomfortable Truth
In hospice and palliative care, few medication classes are as ubiquitous—or as quietly controversial—as benzodiazepines. Lorazepam, alprazolam, clonazepam, and diazepam are encountered daily across care settings, often prescribed for anxiety, agitation, insomnia, dyspnea, and terminal restlessness. For many patients entering hospice, these medications are not new additions but longstanding therapies, sometimes taken continuously for years or even decades.
Despite their familiarity, there is an uncomfortable truth emerging from both the literature and bedside experience: benzodiazepines may contribute to cognitive impairment, functional decline, and diagnostic ambiguity in ways that are highly relevant to hospice care. This creates a tension central to our field. These medications can provide meaningful symptom relief, yet they may also obscure the clinical picture. The challenge, therefore, is not whether benzodiazepines should be used, but whether they are being used intentionally and appropriately in each individual patient.
The Evidence: Association, Not Simplicity
The relationship between benzodiazepine use and dementia risk has been widely studied, with several observational studies and meta-analyses suggesting an association between long-term use and increased risk of cognitive decline. A commonly cited meta-analysis reported approximately a 50% increased risk of dementia among chronic users. However, this data must be interpreted with caution. These studies demonstrate association rather than causation, and the underlying relationship is complex.
Anxiety and insomnia—conditions frequently treated with benzodiazepines—may themselves represent early manifestations of neurodegenerative disease. Additionally, patients prescribed these medications often have baseline characteristics that independently increase dementia risk. Confounding by indication is therefore substantial. Yet even when causality remains uncertain, one point is clear: chronic benzodiazepine use is associated with measurable cognitive effects that are clinically significant. In hospice populations, where cognition and quality of life are central considerations, this association cannot be dismissed.
What Benzodiazepines Do to the Brain: A Palliative Perspective
Benzodiazepines exert their effects through potentiation of GABAergic activity, producing sedation, anxiolysis, and muscle relaxation. However, these same mechanisms contribute to several downstream effects that are particularly relevant in palliative care.
One of the most important impacts is on sleep architecture. Benzodiazepines suppress both slow-wave sleep and REM sleep, the very stages necessary for memory consolidation, emotional processing, and metabolic waste clearance within the brain. As a result, patients may appear to sleep through the night while still experiencing non-restorative sleep. Clinically, this often manifests as increased daytime confusion, fatigue, and worsening delirium, particularly in frail or cognitively vulnerable individuals.
In addition to disrupting sleep, benzodiazepines impair executive function by blunting frontal lobe activity. This can affect planning, attention, organization, and impulse control. The resulting clinical picture—slowed cognition, impaired decision-making, and reduced engagement—can closely resemble early dementia. In older adults, these effects are magnified due to age-related pharmacokinetic changes, increased central nervous system sensitivity, and the cumulative burden of polypharmacy.
Another critical effect is the development of physiologic dependence. With prolonged use, patients adapt to the presence of the medication, and abrupt discontinuation can result in significant withdrawal symptoms, including anxiety, agitation, delirium, and even seizures. Importantly, withdrawal symptoms often mirror the original indication for treatment, making it difficult to distinguish between disease recurrence and medication effect. This creates a clinical scenario in which the medication appears necessary, when in fact it may be perpetuating the very symptoms it was intended to treat.
The Diagnostic Trap in Hospice Care
One of the most underappreciated consequences of long-term benzodiazepine use in hospice populations is the risk of diagnostic misattribution. Patients are frequently referred for evaluation of “possible dementia” or unexplained cognitive decline, yet in some cases, their symptoms are substantially influenced by chronic medication effects rather than irreversible neurodegenerative disease.
These patients often present with impaired executive function, slowed processing speed, memory complaints, and decreased engagement—features that closely mimic dementia syndromes. However, in select cases, careful deprescribing and gradual tapering of benzodiazepines can lead to meaningful cognitive improvement. While not all deficits are reversible, the degree of recovery observed in some patients highlights the importance of considering medication effects as part of the differential diagnosis. Failure to do so risks labeling patients inaccurately and missing opportunities to improve their quality of life.
Benzodiazepines in Hospice: When They Are Appropriate
It is important to emphasize that benzodiazepines remain an essential component of hospice care when used appropriately. They are highly effective for acute anxiety, panic, and distress, and they play a valuable role in the management of dyspnea with an anxiety component. They are also critical in the treatment of seizure disorders, alcohol or benzodiazepine withdrawal, and, in selected cases, terminal agitation or palliative sedation.
In these contexts, the goal is immediate symptom relief rather than long-term cognitive preservation. Benzodiazepines can provide rapid and meaningful comfort, and their use is often entirely appropriate. The issue, therefore, is not their existence within hospice care, but rather the context, duration, and intent behind their use.
Where We Get Into Trouble: Chronic Daily Use
The greatest challenges arise with chronic, scheduled benzodiazepine use, particularly in older adults entering hospice care. Many patients have been maintained on daily therapy for months or years, often without periodic reassessment of ongoing need or effectiveness.
In these cases, benzodiazepines may contribute to a range of complications, including increased fall risk, worsening delirium, diminished cognitive clarity, and reduced ability to engage meaningfully with family and caregivers. They may also complicate prognostication by blurring the distinction between medication effect and disease progression. This is especially relevant in hospice, where accurate assessment of decline is central to both clinical care and regulatory compliance.
The Hospice Dilemma: Deprescribe or Maintain?
Decisions regarding benzodiazepine management in hospice are rarely straightforward and must be individualized based on the patient’s clinical context. Prognosis plays a central role. In patients with a prognosis of days to weeks, the priority is comfort, and continuation of benzodiazepines is often appropriate. In patients with a longer expected trajectory, however, there may be an opportunity to reassess their role.
Symptom burden must also be carefully evaluated. Clinicians should consider whether the medication is providing true relief or simply maintaining physiologic dependence. Equally important are the patient’s goals of care. Some patients may prioritize alertness and meaningful interaction, while others may prioritize sedation and relief from distress. Any decision to taper must also account for the risk of withdrawal, which necessitates a slow, carefully monitored approach.
A Practical Approach to Benzodiazepines in Hospice
A thoughtful approach begins with reframing the conversation. Rather than presenting benzodiazepines as inherently harmful, it is often more effective to explore whether they may be contributing to the patient’s current symptoms. This allows patients and families to engage in the decision-making process without feeling that a beneficial therapy is being arbitrarily withdrawn.
Clinicians should then assess the balance of benefit and burden, considering whether the medication aligns with the patient’s goals and improves quality of life. When appropriate, a gradual taper may be considered, recognizing that this process often requires months rather than weeks. Close monitoring is essential to distinguish between withdrawal effects and underlying symptoms.
Alternative therapies should also be explored when appropriate, including non-pharmacologic interventions and, in selected cases, other medication classes. The goal is not to eliminate benzodiazepines categorically, but to ensure that their use remains purposeful and aligned with patient-centered care.
Regulatory and Documentation Implications
From a regulatory perspective, benzodiazepine use intersects with several areas of scrutiny, including fall risk, polypharmacy, and the appropriateness of symptom-driven prescribing. Hospice providers must be prepared to clearly document the clinical rationale for ongoing use, as well as evidence of regular reassessment.
Documentation should reflect the indication for therapy, the patient’s response, any discussions regarding risks and benefits, and the alignment of treatment decisions with goals of care. In an environment of increasing regulatory oversight, this level of clarity is essential not only for compliance, but for ensuring high-quality, defensible care.
The Bigger Picture: What Are We Treating?
At its core, the issue of benzodiazepine use in hospice care reflects a broader challenge: distinguishing between disease progression and potentially reversible contributors to decline. In a population where multiple factors often converge, medications can play a significant and sometimes underrecognized role.
Benzodiazepines, in particular, have the potential to blur the clinical picture, leading to misinterpretation of symptoms and missed opportunities for intervention. As clinicians, our responsibility is to maintain diagnostic clarity to the extent possible, even within the constraints of serious illness. This requires ongoing vigilance, critical thinking, and a willingness to question long-standing assumptions.
Conclusion: Thoughtful Use, Not Reflexive Use
Benzodiazepines are powerful and valuable medications, but they are not without consequence. In hospice and palliative care, where the goals of treatment are deeply individualized and often evolving, their use must be guided by intention rather than habit.
They should be used when they provide clear and meaningful comfort. They should be questioned when they contribute to cognitive impairment or obscure the clinical picture. Most importantly, they should be reassessed regularly as the patient’s condition and goals of care change.
Ultimately, the goal is not to eliminate benzodiazepines from hospice care, but to ensure that their use reflects a thoughtful, patient-centered approach. In doing so, we can better align our treatments with the needs, values, and experiences of the patients we serve.
References:
American Geriatrics Society Beers Criteria Update Expert Panel (2023) ‘American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults’, Journal of the American Geriatrics Society, 71(7), pp. 2052–2081.
American Society of Addiction Medicine (2025) Joint clinical practice guideline on benzodiazepine tapering.
Billioti de Gage, S., Bégaud, B., Bazin, F., Verdoux, H., Dartigues, J.F., Pérès, K., Kurth, T. and Pariente, A. (2012) ‘Benzodiazepine use and risk of dementia: prospective population based study’, BMJ, 345, e6231.
Billioti de Gage, S., Moride, Y., Ducruet, T., Kurth, T., Verdoux, H., Tournier, M., Pariente, A. and Bégaud, B. (2014) ‘Benzodiazepine use and risk of Alzheimer’s disease: case-control study’, BMJ, 349, g5205
Centers for Medicare & Medicaid Services (CMS) (2024) State Operations Manual, Appendix PP: Guidance to Surveyors for Long Term Care Facilities. Baltimore, MD: CMS.
Croke, L. (2019) ‘Deprescribing benzodiazepine receptor agonists for insomnia in adults’, American Family Physician, 99(1), pp. 57–58.
Edinoff, A.N., Nix, C.A., Hollier, J., Sagrera, C.E., Delacroix, B.M., Abubakar, T., Kaye, A.D., Cornett, E.M., Garcia, A.J., Richards, J.R. and Kaye, A.M. (2021) ‘Benzodiazepines: uses, dangers, and clinical considerations’, Neurology International, 13(4), pp. 594–607.
